Recordati S.a. Chemical and Pharmaceutical Company

Recordati S.a.

Pharmaceutical Company

Recordati S.a. Chemical

Rodolfo Testa

Amedeo Leonardi

Gianni Motta

Carlo Riva

Dante Nardi

Gabriele Graziani

Giorgio Sironi

Silvano Casadio

Luciano Guarneri

Carlo Boi

Abraham Sartani

N,N-Disubstituted diazocycloalkanes of the formula I 

N,N-disubstituted diazocycloalkanes

Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &#x3b1;-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

Use of selective antagonists of the &#x3b1;1B-adrenergic receptor for improvement of sexual dysfunction

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are diarylalkylpiperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HTreceptors, for treating disorders of the lower urinary tract.

Diarylalkylpiperazines active on the lower urinary tract

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(5-substituted-7-oxo-7H-thieno&lsqb;3,2-b&rsqb;pyran-3-carbonylamino)alkyl&rsqb;piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neutogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

Thienopyranecarboxamide derivatives

The treatment of neuromuscular dysfunction of the lower urinary tract by compounds which selectively inhibit the COX-2 isozyme is described. The compounds concerned inhibit the COX-2 isozyme with a potency at least 10-fold, and preferably at least 100-fold, greater than their potency on the COX-1 isozyme.

Use of selective COX-2 inhibitors for the treatment of urinary incontinence

The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.

1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(5-substituted-7-oxo-7H-thieno&lsqb;3,2-b&rsqb;pyran-3-carbonylamino)alkyl&rsqb;piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha -adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). The compounds are also useful in the treatment of excessive intraocular pressure, cardiac arrhythmia, erectile dysfunction, sexual dysfunction, and for inhibiting cholesterol synthesis or reducing sympathetically mediated pain.

The invention is directed to compounds of Formula I:

Thienopyrancecarboxamide derivatives

Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &agr;,-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

Use of selective antagonists of the &agr;1B-adrenergic receptor for improvement of sexual dysfunction

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are aniline derivatives substituted at position 2 of the aniline ring. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT.sub.1A receptors, for treating disorders of the lower urinary tract.

1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2

The present invention discloses compositions and methods for treating neuromuscular dysfunction of the lower urinary tract in mammals, including humans, using serotonin 5-HT.sub.1A receptor antagonist compounds that exert their inhibitory effects via pre-synaptic (somatodendritic) and post-synaptic antagonism.

Use of 5-HT.sub.1A receptor antagonists for the treatment of urinary

Quinazolinyl-amino derivatives having .alpha.-antagonist activity

The subject invention provides methods for preventing, retarding, or reducing atherosclerotic lesions or atherosclerotic degradation of aterial walls or treating atherosclerosis comprising administering to a mammal in need of such prevention, retardation, reduction or treatment at least one compound having the formula I: ##STR1## wherein: Ph is phenyl,

1,4-Dihydropyridines useful for prevention or reduction of

The present invention provides S-enantiomers of 1,4-dihydropyridines useful for the treatment of heart failure, preparation of compositions thereof and a method for the treatment of hypertension and heart failure comprising administration of these compounds.

Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating

This invention provides bicyclic heterocyclic derivatives and their pharmaceutically acceptable salts useful for the treatment of hypertension, urethral and lower urinary tract contractions, and other disorders. The compounds are also useful for binding .alpha..sub.1 -adrenergic and 5HT.sub.1A serotonergic receptors, in vitro or in vivo.

Growing community of inventors

Vignate, Italy

Rodolfo Testa